Journal Mobile Options
Table of Contents
Vol. 100, No. 1-4, 2003
Issue release date: 2003

FMR2 function: insight from a mouse knockout model

Gu Y. · Nelson D.L.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The FMR2 gene is dysregulated by the fragile X E triplet repeat expansion in patients with FRAXE mental retardation syndrome. A CCG triplet, located in the 5′ untranslated region of the FRAXE gene undergoes expansion and methylation in these patients, eliminating detectable gene transcription. FRAXE syndrome is distinct from fragile X syndrome, a more common genetic form of mental retardation caused by expansion and methylation of a similar repeat in the FMR1 gene located 600 kb proximal to FRAXE. FRAXE syndrome is rare, and patients’ phenotypes are highly variable, leading to difficulties with predicting specific FMR2 functions based on the human disease. Recently, Lilliputian(Lilli), a Drosophila FMR2 orthologue, was identified; this gene has been linked with several signal transduction pathways, including the transforming growth factor-β (TGF-β) pathway, the Raf/MEK/MAP kinase (MAPK) pathway, and the P13K/PKB pathway. Mutation of Lilli shows defects in germinal band extension, cytoskeletal structure, cell growth, and organ development. The Lilli gene suggests possible functions for FMR2 (and related genes) in humans and mice, but cannot predict specific functions. Modeling Fmr2 mutation in the mouse will be useful to understand specific functions of this gene in vertebrates. This review presents what has been learned thus far from the Fmr2 knockout mouse model and suggests future studies on this model in order to compare it with the human FRAXE mental retardation disorder, Lilli mutants in Drosophila and other mouse models of genes in this family.   

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Albright S, Lachiewicz AM, Tarleton JC, Rao KW, Schwartz CE, Richie R, Tennison MB, Aylsworth AS: Fragile X phenotype in a patient with a large de novo deletion in Xq27→q28. Am J med Genet 51:294–297 (1994).
  2. Allen K, Gleeson JG, Bagrodia S, Partington MW, MacMillan JC, Cerione RA, Mulley JC, Walsh CA: PAK3 mutation in nonsyndromic X-linked mental retardation. Nature Genet 20:25–30 (1998).
  3. Barnicoat A, Wang Q, Turk J, Green E, Mathew CG, Flynn G, Buckle V, Hirst M, Davies K, Bobrow M: Clinical, cytogenetic, and molecular analysis of three families with FRAXE. J med Genet 34:13–17 (1997).
  4. Biancalana V, Taine L, Bouix JC, Finck S, Chauvin A, De Verneuil H, Knight SJ, Stoll C, Lacombe D, Mandel JL: Expansion and methylation status at FRAXE can be detected on EcoRI blots used for FRAXA diagnosis: analysis of four FRAXE families with mild mental retardation in males. Am J hum Genet 59:847–854 (1996).
  5. Billuart P, Bienvenu T, Ronce N, des Portes V, Vinet MC, Zemni R, Roest Crollius H, Carrie A, Fauchereau F, Cherry M, Briault S, Hamel B, Fryns JP, Beldjord C, Kahn A, Moraine C, Chelly J: Oligophrenin-1 encodes a rhoGAP protein involved in X-linked mental retardation. Nature 392:923–926 (1998).
  6. Bliss TVP, Collingridge GL: A synaptic model of memory long-term potentiation in the hippocamppus. Nature 361:31–39 (1993).
  7. Britanova O, Lukyanov S, Gruss P, Tarabykin V: The Mouse Laf4 gene: exon/intron organization, cDNA sequence, alternative splicing, and expression during central nervous system development. Genomics 80:31–37 (2002).
  8. Carbonell P, Lopez I, Gabarron J, Bernabe MJ, Lucas JM, Guitart M, Gabau E, Glover G: FRAXE mutation analysis in three Spanish families. Am J med Genet 64:434–440 (1996).
  9. Chakrabarti L, Knight SJ, Flannery AV, Davies KE: A candidate gene for mild mental handicap at the FRAXE fragile site. Hum molec Genet 5:275–282 (1996).
  10. Chakrabarti L, Bristulf J, Foss GS, Davies KE: Expression of the murine homologue of FMR2 in mouse brain and during development. Hum molec Genet 7:441–448 (1998).
  11. D’Adamo P, Menegon A, Lo Nigro C, Grasso M, Gulisano M, Tamanini F, Bienvenu T, Gedeon AK, Oostra B, Wu SK, Tandon A, Valtorta F, Balch WE, Chelly J, Toniolo D: Mutations in GDI1 are responsible for X-linked non-specific mental retardation. Nature Genet 19:134–139 (1998).
  12. Dobson C, Warren AJ, Pannell R, Forster A, Rabbitts TH: Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial LacZ gene. EMBO J 19:843–851 (2000).
  13. English J, Sweatt JD: A requirement for the mitogen-activated protein kinase cascade in hippocampal long term potentiation. J biol Chem 272:19103–19106 (1997).
  14. Estable M, Naghavi MH, Kato H, Xiao H, Qin J, Vahlne A, Roeder RG: MCEF, the newest member of the AF4 family of transcription factors involved in leukemia, is a positive transcription elongation factor-b-associated protein. J Biomed Sci 9:234–245 (2002).
  15. Fengler S, Fuchs S, Konig R, Arnemann J: Mosaicism for FMR1 and FMR2 deletion: a new case. J med Genet 39:200–201 (2002).
  16. Gecz J: The FMR2 gene, FRAXE and non-specific X-linked mental retardation: clinical and molecular aspects. Ann hum Genet 64:95–106 (2000).
  17. Gecz J, Mulley JC: Characterisation and expression of a large, 13.7-kb FMR2 isoform. Eur J hum Genet 7:157–162 (1999).
  18. Gecz J, Gedeon AK, Sutherland GR, Mulley JC: Identification of the gene FMR2, associated with FRAXE mental retardation. Nature Genet 13:105–108 (1996).
  19. Gecz J, Bielby S, Sutherland GR, Mulley JC: Gene structure and subcellular localization of FMR2, a member of a new family of putative transcription activators. Genomic 44:201–213 (1997a).
  20. Gecz J, Oostra BA, Hockey A, Carbonell P, Turner G, Haan EA, Sutherland GR, Mulley JC: FMR2 expression in families with FRAXE mental retardation. Hum molec Genet 6:435–441 (1997b).
  21. Gedeon A, Meinanen M, Ades LC, Kaariainen H, Gecz J, Baker E, Sutherland GR, Mulley JC: Overlapping submicroscopic deletions in Xq28 in two unrelated boys with developmental disorders: identification of a gene near FRAXE. Am J hum Genet 56:907–914 (1995).
  22. Gu Y, McIlwain KL, Weeber EJ, Yamagata T, Xu B, Antalffy BA, Reyes C, Yuva-Paylor L, Armstrong D, Zoghbi H, Sweatt JD, Paylor R, Nelson DL: Impaired conditioned fear and enhanced long-term potentiation in Fmr2 knock-out mice. J. Neurosci 22:2753–2763 (2002).
  23. Gu Y, Nakamura T, Alder H, Prasad R, Canaani O, Cimino G, Croce CM, Canaani E: The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 71:701–708 (1992).
  24. Gu Y, Nelson DL: AF5q31 knockout mouse model: exploring the functions of FMR2/AF4 gene family. 8th international fragile X conference Chicago: G9 (2002).
  25. Gu Y, Shen Y, Gibbs RA, Nelson DL: Identification of FMR2, a novel gene associated with the FRAXE CCG repeat and CpG island. Nature Genet 13:109–113 (1996).
  26. Hamel B, Smits AP, de Graaff E, Smeets DF, Schoute F, Eussen BH, Knight SJ, Davies KE, Assman-Hulsmans CF, Oostra BA: Segregation of FRAXE in a large family: clinical, psychometric, cytogenetic, and molecular data. Am J hum Genet 55:923–931 (1994).
  27. Harrison S, Houzelstein D, Dunwoodie SL, Beddington RS: Sp5, a new member of the Sp1 family, is dynamically expressed during development and genetically interacts with Brachyury. Dev Biol 227:358–372 (2000).
  28. Hillman M, Gecz J: Fragile XE-associated familial mental retardation protein 2 (FMR2) acts as a potent transcription activator. J hum Genet 46:251–259 (2001).
  29. Holscher C: Synaptic plasticity and learning and memory: LTP and beyond. J Neurosci Res 58:62–75 (1999).
  30. Ihn H, Trojanowska M: Sp3 is a transcriptional activator of the human alpha2(I) collagen gene. Nucl Acids Res 25:3712–3717 (1997).
  31. Isnard P, Core N, Naquet P, Djabali M: Altered lymphoid development in mice deficient for the mAF4 proto-oncogene. Blood 96:705–710 (2000).
  32. Kadonaga J., Carner KR, Masiarz FR, Tjian R: Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell 51:1079–1090 (1987).
  33. Kingsley C, Winoto A: Cloning of GT box-binding proteins: a novel Sp1 multigene family regulating T-cell receptor gene expression. Mol cell Biol 12:4251–4261 (1992).
  34. Knight S, Flannery AV, Hirst MC, Campbell L, Christodoulou Z, Phelps SR, Pointon J, Middleton-Price HR, Barnicoat A, Pembrey ME, et al: Trinucleotide repeat amplification and hypermethylation of a CpG island in FRAXE mental retardation. Cell 74:127–134 (1993).
  35. Knight S, Ritchie RJ, Chakrabarti L, Cross G, Taylor GR, Mueller RF, Hurst J, Paterson J, Yates JR, Dow DJ, Davies KE: A study of FRAXE in mentally retarded individuals referred for fragile X syndrome (FRAXA) testing in the United Kingdom. Am J hum Genet 58:906–913 (1996).
  36. Knight S, Voelckel MA, Hirst MC, Flannery AV, Moncla A, Davies KE: Triplet repeat expansion at the FRAXE locus and X-linked mild mental handicap. Am J hum Genet 55:81–86 (1994).
  37. Kremer E, Pritchard M, Lynch M, Yu S, Holman K, Baker E, Warren ST, Schlessinger D, Sutherland GR, Richards RI: Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science 252:1711–1714 (1991).
  38. Kutsche K, Yntema H, Brandt A, Jantke I, Nothwang HG, Orth U, Boavida MG, David D, Chelly J, Fryns JP, Moraine C, Ropers HH, Hamel BC, van Bokhoven H, Gal A: Mutations in ARHGEF6, encoding a guanine nucleotide exchange factor for Rho GTPases, in patients with X-linked mental retardation. Nature Genet 26:247–250 (2000).
  39. Lander E, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, et al: International Human Genome Sequencing Consortium: Initial sequencing and analysis of the human genome. Nature 409:860–921 (2001).
  40. Liao X, Ma C, Trask B, Massa H, Gilbert DJ, Staudt LM, Jenkins NA, Copeland NG: LAF4 maps to mouse chromosome 1 and human chromosome 2q11.2→q12. Mammal Genome 7:467–468 (1996).
  41. Lo Nigro C, Faravelli F, Cavani S, Perroni L, Novello P, Vitali M, Bricarelli FD, Grasso M: FRAXE mutation in a mentally retarded subject and in his phenotypically normal twin brother. Eur J hum Genet 8:157–162 (2000).
  42. Ma C, Staudt LM: LAF-4 encodes a lymphoid nuclear protein with transactivation potential that is homologous to AF-4, the gene fused to MLL in t(4;11) leukemias. Blood 87:734–745 (1996).
  43. Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER: Control of memory formation through regulated expression of a CaMKII transgene. Science 274:1678–1683 (1996).
  44. Mazzocco M, Myers GF, Hamner JL, Panoscha R, Shapiro BK, Reiss AL: The prevalence of the FMR1 and FMR2 mutations among preschool children with language delay. J Pediatr 132:795–801 (1998).
  45. Mckernan M, Shinnick-Gallangher P: Fear conditioning induces a lasting potentiation of synaptic currents in vitro. Nature 390:607–611 (1997).
  46. Merienne K, Jacquot S, Pannetier S, Zeniou M, Bankier A, Gecz J, Mandel JL, Mulley J, Sassone-Corsi P, Hanauer A: A missense mutation in RPS6KA3 (RSK2) responsible for non-specific mental retardation. Nature Genet 22:13–14 (1999).
  47. Miller W, Skinner JA, Foss GS, Davies KE: Localization of the fragile X mental retardation 2 (FMR2) protein in mammalian brain. Eur J Neurosci 12:381–384 (2000).
  48. Moore S, Strain L, Cole GF, Miedzybrodzka Z, Kelly KF, Dean JC: Fragile X syndrome with FMR1 and FMR2 deletion. J med Genet 36:565–566 (1999).
  49. Mulley J, Yu S, Loesch DZ, Hay DA, Donnelly A, Gedeon AK, Carbonell P, Lopez I, Glover G, Gabarron I, et al: FRAXE and mental retardation. J med Genet 32:162–169 (1995).
  50. Murgia A, Polli R, Vinanzi C, Salis M, Drigo P, Artifoni L, Zacchello F: Amplification of the Xq28 FRAXE repeats: extreme phenotype variability? Am J med Genet 64:441–444 (1996).
  51. Murray A, Webb J, Dennis N, Conway G, Morton N: Microdeletions in FMR2 may be a significant cause of premature ovarian failure. J med Genet 36:767–770 (1999).
  52. Nelson DL: FRAXE mental retardation and other folate-sensitive fragile sites. Genetic instabilities and hereditary neurological diseases, Wells RD, Warren ST (eds), pp 65–74 (Academic Press, San Diego 1998).
  53. Nilson I, Reichel M, Ennas MG, Greim R, Knorr C, Siegler G, Greil J, Fey GH, Marschalek R: Exon/intron structure of the human AF-4 gene, a member of the AF-4/LAF-4/FMR-2 gene family coding for a nuclear protein with structural alterations in acute leukaemia. Br J Haematol 98:157–169 (1997).
  54. Oberle I, Rousseau F, Heitz D, Kretz C, Devys D, Hanauer A, Boue J, Bertheas MF, Mandel JL: Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 252:1097–1102 (1991).
  55. Parrish J, Oostra BA, Verkerk AJ, Richards CS, Reynolds J, Spikes AS, Shaffer LG, Nelson DL: Isolation of a GCC repeat showing expansion in FRAXF, a fragile site distal to FRAXA and FRAXE: Nature Genet 8:229–235 (1994).
  56. Roberson E, English JD, Adams JP, Selcher JC, Kondratick C, Sweatt JD: The mitogen-activated protein kinase cascade couples PKA and PKC to cAMP response element binding protein phosphorylation in area CA1 of hippocampus. J Neurosci 19:4337–4348 (1999).
  57. Rogan M, VS Ursula, JE LeDoux: Fear conditioned induces associative long-term potentiation in the amygdala. Nature 390:604–607 (1997).
  58. Russo S, Selicorni A, Bedeschi MF, Natacci F, Viziello P, Fortuna R, Pagani G, Dalpra L, Larizza L: Molecular characterization of FRAXE-positive subjects with mental impairment in two unrelated Italian families. Am J med Genet 75:304–308 (1998).
  59. Simone F, Polak PE, Kaberlein JJ, Luo RT, Levitan DA, Thirman MJ: EAF1, a novel ELL-associated factor that is delocalized by expression of the MLL-ELL fusion protein. Blood 98:201–209 (2001).
  60. Song J, Mangold M, Suske G, Geltinger C, Kanazawa I, Sun K, Yokoyama KK: Characterization and promoter analysis of the mouse gene for transcription factor Sp4. Gene 264:19–27 (2001).
  61. Su M, Wisotzkey RG, Newfeld SJ: A screen for modifiers of decapentaplegic mutant phenotypes identifies lilliputian, the only member of the Fragile- X/Burkitt’s Lymphoma family of transcription factors in Drosophila melanogaster. Genetics 157:717–725 (2001).
  62. Sutherland G, Baker E: Characterization of a new rare fragile site easily confused with the fragile X. Hum molec Genet 1:111–113 (1992).
  63. Taki T, Kano H, Taniwaki M, Sako M, Yanagisawa M, Hayashi Y: AF5q31, a newly identified AF4-related gene, is fused to MLL in infant acute lymphoblastic leukemia with ins(5;11)(q31;q13q23). Proc natl Acad Sci, USA 96:14535–14540 (1999).
  64. Tang A, Neufeld TP, Rubin GM, Muller HA: Transcriptional regulation of cytoskeletal functions and segmentation by a novel maternal pair-rule gene, lilliputian. Development 128:801–813 (2001).
  65. Venter J, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, et al: The sequence of the human genome. Science 291:1304–1351 (2001).
  66. Verkerk A, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang FP, et al: Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65:905–914 (1991).
  67. Wittwer F, van der Straten A, Keleman K, Dickson BJ, Hafen E: Lilliputian: an AF4/FMR2-related protein that controls cell identity and cell growth. Development 128:791–800 (2001).
  68. Wolff D, Gustasshaw KM, Zurcher V, Ko L, White W, Weiss L, Van Dyke DL, Schwartz S, Willard HF: Deletions in Xq26.3→q27.3 including FMR1 result in a severe phenotype in a male and variable phenotypes in females depending upon the X inactivation pattern. Hum Genet 100:256–262 (1997).
  69. Yeh R, Lim LP, Burge CB: Computational inference of homologous gene structures in the human genome. Genome Res 11:803–816 (2001).
  70. Yu B, Hess JL, Horning SE, Brown GA, Korsmeyer SJ: Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378:505–508 (1995).

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50